• LevelJump will issue up to 16,666,667 units at $0.15 per unit for gross proceeds of up to $2,500,000
  • Net proceeds from the financing will be used towards acquisitions and for general working capital purposes
  • The offering is expected to close in late January
  • Leveljump Healthcare is a healthcare company with a focus on profitable telehealth solutions as well as primary care services in radiology
  • Shares in Leveljump Healthcare Corp. (JUMP) are down 4.76 per cent on the day, trading at C$0.10 per share at 12:30 pm EST

LevelJump Healthcare (JUMP) will be conducting a non-brokered private placement financing for gross proceeds of up to $2,500,000.

The company will issue up to 16,666,667 units at $0.15 per unit. Each unit will consist of one common share and one common share purchase warrant. Each warrant will entitle the holder to acquire one additional common share of Leveljump at an exercise price of $0.20 with an expiry date of January 31, 2024.

The net proceeds from the financing will be used towards acquisitions and for general working capital purposes.

The offering is expected to close in late January.

Securities issued will be subject to a four-month hold period in accordance with applicable securities laws.

Leveljump Healthcare is a healthcare company with a focus on profitable telehealth solutions as well as primary care services in radiology. The company provides radiology solutions for hospitals, emergency rooms, and private clinics.

Shares in Leveljump Healthcare Corp. (JUMP) are down 4.76 per cent on the day, trading at C$0.10 per share at 12:30 pm EST.

More From The Market Online

Cannabix delivers marijuana breath test to Eastern Canada workplace testing clinic

Cannabix Technologies (CSE:BLO) delivered its Marijuana Breath Test devices to a workplace drug and alcohol testing clinic in eastern Canada.

Biotech company patenting world’s first AI voice test for substance abuse

Biotech company MindBio files a patent application for the world's first AI model to detect substance abuse though vocal analysis.

2 biotech stocks bridging the gap between unmet need and next-gen medicine

Exploring Lunai Bioworks and TheraCryf, two biotech stocks taking early strides towards improving the lives of tens of millions of patients.